WMGI+Logo3.png

JWCA acts as an exchange agent for wright medical group on its $675 million convertible bond exchange, new issuance AND CALL SPREAD ISSUANCE

JUNE 2018 | read press release

Transaction Background

Wright Medical Group’s extremities and biologics businesses averaged nearly 32% revenue growth in 2015 – 2017, and in June 2018, the Company received FDA approval of an injectable form of it’s Augment biologic product.  The Company wanted to take advantage of it’s positive business momentum to refinance its upcoming 2020 Convertible maturity, and hired JWCA as its exchange agent in partnership with PWP as its Capital Markets Advisor

Functioned as an extension of Wright’s team, providing strategic capital structure planning and analysis

Worked closely with the Company to evaluate its refinancing alternatives related to the 2020 Convertible and Call Spread, including the Company’s various execution alternatives (public new issuance, private exchange, etc.)

Provided detailed tactical planning for the refinancing transaction, evaluating all facets of execution in light of:

  • Stock price risk

  • Company open windows

  • Investor mix

  • Pro forma balance sheet and leverage

  • Total cost of capital

Assisted the team with documentation, tax review, and settlement

Provided advice, support and analysis during the execution

Results

Company issued $675mm in a new convertible, with $401mm exchanged from existing investors and $215mm of new capital raised to drive tighter pricing

Avoided stock price risk, as we executed as an overnight after the wall-cross

Refinanced the majority (~68%) of the Company’s 2020 convertible notes at a lower interest rate and higher effective conversion price

  • Reduced coupon from 2.00% to 1.625%

  • Increased conversion price from $29.94 to $33.37 ($40.86 with call spread)

  • Extended maturity by ~3.5 years on $401mm of debt

JWCA’s call spread negotiations resulted in meaningful savings for the Company